Related Experiment Video
Updated: Aug 16, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application
Insights
Cysteamine treatment for nephropathic cystinosis in children shows promise. Gelatin capsules are an effective delivery method, with 50 mg/kg/day normalizing leukocyte cystine levels without side effects.
Area of Science:
- Pediatric Nephrology
- Medical Biochemistry
Background:
- Nephropathic cystinosis is a rare genetic disorder characterized by lysosomal accumulation of cystine.
- Current treatments focus on managing complications and slowing disease progression.
Observation:
- A pilot study evaluated cysteamine treatment in three children with nephropathic cystinosis, two of whom had undergone renal transplantation.
- The study aimed to identify a practical application form and effective dosage for cysteamine therapy.
Findings:
- Cysteamine in gelatin capsules with silicic acid was the most acceptable formulation compared to syrup or suppositories.
- A dosage of 50 mg/kg/day effectively reduced leukocyte cystine content, indicating therapeutic efficacy.
- No adverse side effects were observed, even at higher doses (90 mg/kg/day).
Implications:
- This study suggests a viable and well-tolerated cysteamine treatment regimen for nephropathic cystinosis.
- Further research is needed to confirm its long-term efficacy in preventing disease progression, particularly in transplanted patients or pre-symptomatic infants.
Abstract:
A pilot study with cysteamine treatment was performed in three children with the nephropathic form of cystinosis. Two children underwent renal transplantation shortly before treatment. The aim of the study was to find a practicable form of application and a corresponding effective dose. Cysteamine in gelatine capsules together with 0.2% silicic acid as a dessicator turned out to be the most acceptable galenic form, compared to sirup or suppositories. Among three dosage regimens, the dosage of 50 mg/kg/day is effective as judged by the leucocyte cystine content, even if given in only three doses per day. No side effects of the cysteamine treatment (even at a dose of 90 mg/kg/day) were noted. Whether this treatment is preventing progression of disease will have to be examined either in transplanted patients by measuring non-renal parameters or in very young infants with cystinosis whose kidneys are not damaged yet.
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:55Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
Published on: July 4, 2018
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Urinary Tract Calculi III: Medical Management